EP Patent

EP3922639A1 — Anthelmintic depsipeptide compounds

Assigned to Boehringer Ingelheim Animal Health USA Inc · Expires 2021-12-15 · 4y expired

What this patent protects

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The inventi…

USPTO Abstract

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

Drugs covered by this patent

Patent Metadata

Patent number
EP3922639A1
Jurisdiction
EP
Classification
Expires
2021-12-15
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Animal Health USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.